Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model

Y-L Chen¹,², C-Y Wang²,³, F-Y Yang¹,³, B-S Wang¹,³, JY Chen³, L-T Lin⁴, J-D Leu⁴, S-J Chiu⁵, F-D Chen⁶, Y-J Lee*¹,4,7 and WR Chen*¹,8

Stimulation of the host immune system is crucial in cancer treatment. In particular, nonspecific immunotherapies, when combined with other traditional therapies such as radiation and chemotherapy, may induce immunity against primary and metastatic tumors. In this study, we demonstrate that a novel, non-toxic immunoadjuvant, glycated chitosan (GC), decreases the motility and invasion of mammalian breast cancer cells in vitro and in vivo. Lung metastatic ratios were reduced in 4T1 tumor-bearing mice when intratumoral GC injection was combined with local high-intensity focused ultrasound (HIFU) treatment. We postulate that this treatment modality stimulates the host immune system to combat cancer cells, as macrophage accumulation in tumor lesions was detected after GC-HIFU treatment. In addition, plasma collected from GC-HIFU-treated tumor-bearing mice exhibited tumor-specific cytotoxicity. We also investigated the effect of GC on epithelial–mesenchymal transition-related markers. Our results showed that GC decreased the expression of Twist-1 and Slug, proto-oncogenes commonly implicated in metastasis. Epithelial-cadherin, which is regulated by these genes, was also upregulated. Taken together, our current data suggest that GC alone can reduce cancer cell motility and invasion, whereas GC-HIFU treatment can induce immune responses to suppress tumor metastasis in vivo.

Cell Death and Disease (2014) 5, e1178; doi:10.1038/cddis.2014.159; published online 17 April 2014

Subject Category: Cancer

Metastasis is a major cause of cancer treatment failure and mortality. Metastasis to distant organ sites requires enhanced cell motility and invasion. An ideal cancer treatment modality should suppress and eradicate metastasis; however, effective methods are yet to be developed.

Immunotherapy holds great promise in cancer treatment, as it stimulates the host immune system to target cancer cell surface markers to achieve therapeutic effects. These anti-cancer immunological responses can be augmented with cytokines or interleukins. Thus, the use of immunoadjuvants in conjunction with direct cancer treatment can stimulate systemic, tumor-specific immunity, as is the case with the synergistic use of immunoadjuvants in optical or laser-based therapies.

Glycated chitosan (GC), a novel immunoadjuvant, is derived from chitosan, which is a linear polysaccharide composed of d-glucosamine and N-acetyl-d-glucosamine through (1→4) linkage. GC contains d(+) galactose molecules and is water soluble, allowing for a wide variety of biomedical applications. When combined with laser irradiation, GC is effective in treating human breast cancer and melanomas. In addition, preclinical studies and preliminary clinical trials have shown that GC, when combined with phototherapy, induces an immunological response against both treated primary tumors and untreated distant metastases. However, it remains unclear whether GC can directly influence tumor cell behavior, such as migration and invasion.

High-intensity focused ultrasound (HIFU) is a newly developed method of noninvasively ablating tumor cells. Although its mechanism remains to be fully determined, preliminary studies show that the acoustic cavitation and the absorbed heat induced by the interaction between ultrasound pulses and microbubbles may puncture cells and cause tissue necrosis and subsequent immune response. In addition, HIFU-induced cellular responses can modulate systemic immunity.

Abbreviations: | GC, glycated chitosan; HIFU, high-intensity focused ultrasound; EMT, epithelial–mesenchymal transition; mRFP, monomeric red fluorescence protein; E-cadherin, epithelial-cadherin; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay; EDTA, ethylenediaminetetraacetic acid

Received 02.1.14; revised 13.3.14; accepted 13.3.14; Edited by A Stephanou
antitumor immunity.\textsuperscript{19,22} Furthermore, HIFU-mediated tissue destruction via cavitation can be augmented by intravenous administration of microbubbles.

We investigated the \textit{in vitro} effect of GC on the motility and invasion of murine 4T1 breast cancer cells and human MDA-MB-231 breast cancer cells. We also studied the \textit{in vivo} effect of GC and microbubbles/HIFU on these cell lines with bioluminescent imaging of tumor progression in mice using a multicistronic reporter gene system. Furthermore, we analyzed the influence of GC on epithelial–mesenchymal transition (EMT) of cancer cells as well as on GC-HIFU induced antitumor immunity.

Results

Reduction of motility and invasion of breast cancer cells by GC. We used a wound healing assay to measure the migration rate of 4T1 cells with and without GC treatment (100 \( \mu g/mL \) of GC for 24 h). GC significantly reduced the motility of 4T1 cells compared with the untreated control for up to 6 h (Figure 2a). Cell migration rates were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA) (Figure 1b).

Subsequently, we performed an \textit{in vitro} invasion assay using Matrigel-coated transwells, which showed that GC also reduced the invasion of 4T1 cells compared with untreated controls (Figures 1c and d). Reduced cell migration and invasion were also detected in human MDA-MB-231 breast cancer cells treated by GC (Figures 1e and f). The dose and treatment duration have been described in the Materials and Methods. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazoliumbromide (MTT) assays showed that viability of both 4T1 and MDA-MB-231 cells was not significantly affected by GC up to a concentration of 250 \( \mu g/mL \) (Figure 1g), suggesting that operational levels of GC were non-cytotoxic.

Transfection of multicistronic reporter genes to 4T1 cells for the purpose of \textit{in vivo} imaging. A new 4T1_PB3R line of cells was created as described in the Materials and Methods. These cells exhibited high luciferase activity as measured by luminescent assay (Figure 2a). The expression of monomeric red fluorescence protein (mRFP) in 4T1_PB3R cells was pronounced compared with that of parental 4T1 cell, as visualized under fluorescence microscope (Figure 2b). The growth rate (Figure 2c) and invasion rate (Figure 2d) of 4T1_PB3R cells were the same as that of the parent 4T1 cells. In addition, the viability of 4T1_PB3R cells was not affected by GC, even at a concentration up to 250 \( \mu g/mL \) (Figure 2e). These results indicate that it is appropriate to use the 4T1_PB3R cell line as a surrogate for monitoring the behavior of 4T1 tumor cells \textit{in vivo} via reporter gene imaging.

Suppression of tumor metastasis by GC-HIFU treatment. 4T1_PB3R cells were subcutaneously implanted into Balb/C mice. After tumors reached a size of 100 mm\(^3\), tumor-bearing mice were injected with microbubbles via tail vein and treated with HIFU, followed by intratumoral injection of GC (Figure 3a, see Materials and Methods). Tumor-bearing mice were also treated with GC only or HIFU only. The bioluminescent images showed that in untreated mice, tumors metastasized to various locations within 28 days of implantation (Figure 3b). Tumor metastasis was also detectable in mice treated with GC only or HIFU only, but was suppressed in GC-HIFU-treated mice (Figure 3b). Bioluminescent signals from outside the primary tumor in mice of different experimental groups were detected and compared with that of the untreated control group. It appears that GC-HIFU-treated mice showed reduced bioluminescent signals in non-primary tumor sites, suggesting inhibited metastasis (Figure 3c).

Although 4T1 cells metastasize to various primary organs, including the lung, liver, bone and brain, we focused on lung metastases in this study because they occurred in all untreated mice (data not shown). We collected lung tissue from tumor-bearing mice for histological analysis 4 weeks after each treatment. Lung metastases were noticeably reduced in mice treated by GC-HIFU compared with all other groups (Figure 3d). The size and the number of nodules in affected lungs were visualized and measured (Supplementary Figure 1). These findings strongly suggest that GC and HIFU have a synergistic effect on the suppression of lung metastasis of breast cancer.

Accumulation of macrophages in tumors after GC-HIFU treatment. We measured macrophage activity to demonstrate the immunomodulatory effect of GC-HIFU treatment. Tumor sections were collected 2 weeks after GC, HIFU or GC-HIFU treatment. Immunohistochemical (IHC) staining analysis was used to detect antibodies against the F4/80 protein, a macrophage marker, on each tumor section. There was an accumulation of F4/80 markers in primary tumors treated by GC-HIFU (Figure 4a). The results of IHC were also quantified by counting the number of F4/80-stained cells in tumor sections (Figure 4b). Therefore, GC-HIFU treatment may enhance the innate immune response. Whether this effect leads to modulation of metastasis is unknown and needs to be further investigated.

Cytotoxic effects of plasma from GC-HIFU-treated tumor-bearing mice. Blood plasma was extracted from tumor-bearing mice 2 weeks after GC, HIFU or GC-HIFU treatment. The plasma was diluted (1:10) in culture medium and added to cultured 4T1_PB3R cells in a 96-well plate. Cytotoxicity was then determined using the MTT assay (Figure 5a). Figure 5b shows that plasma obtained from GC-HIFU-treated mice markedly inhibited the viability of 4T1_PB3R cells compared with plasma from any other treatment group (Figure 5b). On the contrary, the viability of non-tumorigenic NIH-3T3 fibroblasts was not affected by any of these treatments (Figure 5b). These results suggest that GC-HIFU treatment may induce tumor-specific immunity.

Effects of GC on EMT-related markers. Epithelial–mesenchymal transition (EMT) is an important mechanism for promoting metastasis. According to previous reports, Twist-1, Snail, and Slug are upregulated, whereas epithelial cadherin (E-cadherin) is downregulated during EMT.\textsuperscript{23–25} We compared the protein levels of Twist-1, Snail, Slug, and
E-cadherin in 4T1_PB3R cells before and after GC treatment using western blot analysis. Twist-1 levels were slightly reduced after 10 and 100 μg/ml of GC treatment for 24 h; further suppression of Twist-1 and Slug was found up to 48 h, but the expression of Snail was not significantly reduced by GC treatment (Figure 6a). The level of E-cadherin was also upregulated by GC; however, lower concentrations of GC showed a greater impact than higher concentrations (Figure 6a). Densitometric quantification of immunoblots further confirmed this observation (Figure 6b). These results suggest that GC may influence the expression of EMT-related makers, at least in part.

**Discussion**

GC is an effective nonspecific immunoadjuvant for cancer treatment in combination with noninvasive laser photothermal therapy. HIFU can increase the permeability of blood vessels and mediate antitumor immune responses. Thus, we investigated the effect of GC, HIFU, and GC-HIFU on the motility, invasion, and metastatic potential of the 4T1 tumor line. Our wound healing assay and cell migration test show that GC alone reduces cell motility and invasion, despite its lack of direct toxicity toward 4T1 and other cells (Figure 2).
To monitor effectively tumor progression in vivo, we created a new 4T1_PB3R cell line. These cells emit both bioluminescent signals (by luciferase expression) and fluorescent signals (by mRFP expression) that can be used for cell tracking in vivo and in vitro, as shown in Figures 2a and b, while maintaining the properties of their parent 4T1 line, such as growth (Figure 2c), migration (Figure 2d), and GC treatment response (Figure 2e).

Our bioluminescent imaging results indicate that GC-HIFU treatment can reduce the metastatic ratio of 4T1_PB3R breast cancer in mice. It is noteworthy that neither treatment by HIFU nor GC alone had any significant effect on the primary tumor or lung metastases (Figures 3b and c). A recent report proposed that low pressure-pulsed focused ultrasound with microbubbles could promote antitumor immunological responses in a xenograft CT-26 colon tumor animal model. Additionally, pulsatile HIFU has been reported to be beneficial for drug delivery in tumor treatment. Whether this mode can directly stimulate immune responses or enhance immune responses in the presence of an immunostimulator (GC in our case) is unknown. We thus decided to use pulsatile HIFU in combination with GC in our in vivo studies. Although our results did not completely agree with previous findings, a different tumor model, ultrasound apparatus, and treatment parameters, may have led to this discrepancy. Because continuous HIFU provides better thermal therapeutic effects on tumor, it may be used in combination with GC in the future as a comparator to this study. Future investigations could correlate HIFU parameters and tumor growth, as well as address the auxiliary role of GC on pulsatile HIFU delivery. Furthermore, HIFU delivery parameters should be optimized to maximize primary tumor eradication.

In this study, the GC-HIFU combination was successful in inducing accumulation and activation of macrophages in treated tumors compared with treatment by GC or HIFU alone (Figure 4). Although this study demonstrated that GC-HIFU could induce significant immune responses in tumors, it does not exclude the possibility that intratumoral injection using needles may cause enough physical damage to induce immune responses. The use of intratumoral injection of GC

Figure 2 Establishment of a stable 4T1_PB3R cell line for in vivo imaging of tumor progression. (a) Luciferase activity in 4T1_PB3R cells determined using luciferase gene reporter assay. (b) Expression of mRFP in 4T1_PB3R cells but not in parental 4T1 cells was detected using fluorescence microscopy. (c) Comparison of growth rates between 4T1_PB3R cells and 4T1 cells. (d) In vitro invasion of 4T1_PB3R cells and 4T1 cells. (e) Cell viability using MTT assay after treatment with GC of different concentrations.
is based on previous studies; however, other administration routes may be investigated to avoid potent side effects.

We have demonstrated that combined GC-HIFU treatment exhibits a synergistic effect in reducing metastases (Figures 3b and c). However, it is unclear whether GC-HIFU-induced accumulation of macrophages in primary tumors is directly related to reduced lung metastasis in vivo. Because tumor growth at the primary site was not suppressed (Figure 3b), macrophage accumulation may be insufficient to inhibit tumor proliferation. Most interesting is our discovery that plasma extracted from mice treated by GC-HIFU reduces the viability of cultured 4T1 cells but not NIH-3T3 fibroblasts (Figure 5b), suggesting a tumor-specific immunity induced by GC-HIFU. The antimetastatic effects of GC-HIFU may be associated with an increase in cytokine release. However, we used enzyme-linked immunosorbent assay (ELISA) to analyze the level change of tumor necrosis factor-α (TNF-α), and showed no significant difference among all experimental groups (data not shown). Therefore, use of cytokine-based protein array analysis in the future will help us understand which cytokines are implicated in GC-HIFU-mediated systemic immune responses.

We found that GC displays remarkable efficacy in reducing mobility and invasion of 4T1 cells and MDA-MB-231 cells, despite the fact that GC is non-toxic to tumor cells. Thus, we postulate that this GC-mediated suppression is not caused by direct cytotoxicity. GC suppressed the Twist-1 and the Slug transcription factors, and induced E-cadherin expression, but did not suppress the expression of the Snail transcription factor that is also influential in EMT. Twist-1 and Snail have been reported to be essential for the maintenance of late EMT and initiation of EMT, respectively. Because 4T1 breast cancer cells are highly metastatic cells, we speculate that this cell type has entered late EMT so that the expression of Twist-1, but not Snail, was more treatment-susceptible. However, further studies are required to better understand the discrepancy between Snail and other EMT-related marker expression after GC treatment. Although more EMT-related markers should be examined, our current data suggest that GC at least partially inhibits EMT. Moreover, whether GC
influences the change of other migration- and invasion-related molecules, such as matrix metalloproteinases and tissue inhibitor of metalloproteinases family proteins would be of great interest for further investigation. A microarray assay may be helpful to better understand the underlying mechanisms of GC-mediated inhibition of tumor motility and invasion.

Although GC exhibited antimigratory effects on cultured cells, it appeared that GC alone was insufficient to suppress tumor metastasis in animal models. The discrepancies between in vitro and in vivo effects have been reported in various studies.36–39 As shown in our earlier studies, GC may be effective in stimulating a systemic immune response through its interactions with tumor cells at treatment sites.12,13,15 GC's antitumor effect appeared to be mediated by activation of immune cells in vivo, rather than direct inhibition of tumor cell migration, although it is difficult to measure the inhibition effect on tumor cells in vivo. Furthermore, GC was administered about 7 days after tumor cell seeding in mice. Because the antimigratory effects of GC on cell culture were only investigated in an hourly manner (see the wound healing assay), it seems impossible to reflect completely the in vivo results of GC treatment because tumor progression was monitored for several weeks after early treatment of GC.

In summary, our results demonstrate that GC, as an immunoadjuvant, is able to reduce the migration of 4T1 breast cancer cells. This effect is likely associated with suppression of EMT-related molecules. The GC-HIFU-induced immune response was demonstrated through the accumulation of macrophages at tumor lesions as well as potent plasma immunity. Combining GC and HIFU results in a synergistic effect on the reduction of the lung metastatic ratio of 4T1 breast cancer cells in vivo, which may be related to HIFU-mediated direct tumor destruction and GC-mediated antitumor immunity. This combination may become the foundation for a feasible cancer treatment modality, particularly for metastatic cancers.

Materials and Methods

Cell culture. 4T1 cells are triple-negative (lacking the expression of estrogen, progesterone, and Her2/neu receptors) murine breast carcinoma cells that closely mimic human breast cancer in both tumor growth and metastasis. These cells were cultured in RPMI1640 medium (Gibco; Invitrogen Inc., Carlsbad, CA, USA) with 10% fetal bovine serum (HyClone; Thermo, Waltham, MA, USA), 1% penicillin–streptomycin solution (100 μg/mL) (Caisson Laboratories Inc., North Logan, UT, USA), and 1% L-glutamine (200 mM) (Sigma-Aldrich Co., St. Louis, MO, USA). Human triple-negative MDA-MB-231 breast cancer cells and NIH-3T3 cells were maintained in Dulbecco's modified Eagle medium (Gibco; Invitrogen Inc.) with 10% fetal bovine serum, 1% penicillin-streptomycin solution, and 1% L-glutamine (200 mM). Cells were maintained in an incubator containing 5% CO2 at 37 °C and were passaged every 2 days.
GAPDH

Figure 6 Effects of GC on the expression of EMT-related markers. (a) Western blot analysis for Twist-1, Snail, and E-cadherin, after 4T1 cells were treated with GC at indicated doses with different treatment durations. (b) Quantification of band intensity in each blot using densitometry. Each data point represents mean ± S.D. of three independent experiments. *P-value < 0.05 for Twist-1, E-cadherin, and Slug, compared with untreated controls.

Transfection of multistrionic reporter genes to 4T1 cells to create a new 4T1_PB3R cell line. We previously established a stable murine 4T1-PB-2R/PBase breast cancer cell line containing monomeric red fluorescent protein (mRFP) and herpes simplex virus type 1-thymidine kinase reporter genes using the piggyBac transposon system for in vivo tumor imaging. We modified this system by adding a firefly luciferase (luc2) gene to the original dual-cstrionic PB-2R construct to create a new PB-3R construct for two reasons. First, we wanted to overcome the low sensitivity of mRFP for optical imaging. Second, luc2 has a high sensitivity for bioluminescent imaging of metastases. GC treatment. GC (10 mg/ml, dissolved in deionized distilled water) was added to the wells for 24 h. Phosphate-buffered saline (PBS) of the same volume was added with PBS and fresh medium was then added. Wound healing was prepared as described previously. GC (10 mg/ml, dissolved in deionized distilled water) was stored at 4°C overnight. Cultured 4T1 cells grown in exponential phase were treated with 100 μg/ml of GC or left untreated for 24 h and then trypsinized. Cells (1×106) were then mixed with 200 μl serum-free medium and added into each transwell. Each transwell was then placed into a 24-well plate containing 400 μl normal medium in each well. After 24 h of incubation, each transwell was washed with 1× phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde (Sigma-Aldrich Co., St. Louis, MO, USA) for 10 min. The transwells were then incubated in 1.25% crystal violet solution (Sigma-Aldrich Co.) for 2 min. After PBS destaining, the membranes embedded in the transwells were cut and placed onto slides for microscopic visualization. Crystal violet-stained cells on the membrane were then counted.

Cell viability assay. 4T1 cells were seeded in a 96-well plate (800 cells per well) with GC of various concentrations (0, 50, 100, 150, 200, and 250 μg/μl), and incubated at 37°C for 4 days. After removal of the supernatant, 1 mg/ml MTT solution (Sigma-Aldrich Co.) was mixed with serum-free medium and added to each well. The cells were then incubated at 37°C for 3 h. After removal of the MTT solution, 100 μl dimethyl sulfoxide was added to dissolve crystals. The plate was then placed in an ELISA reader (ELISA plate reader, Bio-Tek Instruments, Winooski, VT, USA) and cell viability was determined by light absorption at 570 nm.

Animal tumor model. 4T1 and 4T1_PB3R tumor cells (1×106 in 100 μl serum-free medium) were subcutaneously injected into the upper backs of ~4- to 5-week-old female Balb/c mice (N = 6 for each experimental group) (National Laboratory Animal Center, Taipei, Taiwan). Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Yang-Ming University (Taipei, Taiwan; approval number: 1011103).

When the tumors became palpable, their dimensions were measured via caliper twice a week. We estimated tumor volume with the equation volume = length (mm) × width (mm)²/2.41 GC and HIFU treatment of animal tumors. Before HIFU treatment, the skin overlying the tumor was epilated and covered with ultrasound transmission gel (Pharmaceutical Innovations, Newark, NJ, USA). The ultrasound contrast agent used in this procedure contained phospholipid-coated microbubbles with a mean diameter of 2.5 μm, at a concentration of 1×10⁸–5×10¹⁰ bubbles per ml.

The setup for the transducer-driving system was the same as that of our previous work. After HIFU, a 100-μl GC solution (10 mg/ml) was injected into the center and three additional random locations in each tumor using a 27G needle as described in previous reports, with slight modifications.61

In vivo bioluminescent imaging. 4T1_PB3R tumor cells expressing a firefly luciferase gene were subcutaneously injected into the upper backs of Balb/c mice. Each tumor-bearing mouse (N = 6 for each experimental group) then received an intraperitoneal injection of 150 mg/kg d-luciferin (Caliper Co., Hopkinton, MA, USA). After 15 min, animals were anesthetized with 2% isofluorane, and luminescent signals were detected via IVIS50 system (Xenogen Co., Alameda, CA, USA). Region of interest tracings were drawn around each tumor using ImageJ software (version 1.46).

Cell Death and Disease

The wound healing rate was determined by visualizing cell migration to the scraped area using light microscopy, and images were acquired and analyzed using ImageJ software (version 1.46).

In vitro invasion assay. Matrigel (BD Biosciences, San Jose, CA, USA) was mixed with 25 μl serum-free medium at a ratio of 1:4, added into transwells (24 Well Millicell; 8.0 μm; Millipore Co., Billerica, MA, USA), and then incubated at 37°C overnight. Cultured 4T1 cells grown in exponential phase were treated with 100 μg/ml of GC or left untreated for 24 h and then trypsinized. Cells (1×10⁶) were then mixed with 200 μl serum-free medium and added into each transwell. Each transwell was then placed into a 24-well plate containing 400 μl normal medium in each well. After 24 h of incubation, each transwell was washed with 1× phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde (Sigma-Aldrich Co., St. Louis, MO, USA) for 10 min. The transwells were then incubated in 1.25% crystal violet solution (Sigma-Aldrich Co.) for 2 min. After PBS destaining, the membranes embedded in the transwells were cut and placed onto slides for microscopic visualization. Crystal violet-stained cells on the membrane were then counted.
We also performed IHC analysis of macrophage markers in primary tumors. Tumor sections were treated with antigen retrieval solution (100 °C 2.2, 2.2, 2.2- (ethane-1,2-diyldinitril)tetraacetic acid (EDTA), pH = 8) for 25 min and cooled on ice for 30 min. The sections were subsequently blocked with 3% H2O2 and protein blocking reagent (Biogenex Laboratories, San Ramon, CA, USA) in the dark and then incubated with anti-mouse F4/80 antibody (eBioscience Inc., San Diego, CA, USA) for 2 h, followed by horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h. Finally, tissue sections were incubated with Liquid DAB + Substrate Chromogen System (Dako North America Inc., Carpinteria, VA, USA) until a brown color developed, and then counterstained with hematoxylin. The slides were visualized under light microscopy, entire tissue sections were examined, and three random regions were selected and photographed using a digital camera.

**Plasma extraction.** Mice (N = 6 for each experimental group) were treated with GC and HIHIFU as described above and killed using cervical dislocation. Blood was immediately collected via cardiac puncture using a 26 G needle and a syringe filled with 120 mg/ml EDTA. Extracted blood was centrifuged at 1000 r.p.m. at 4 °C for 10 min. The supernatant was then collected and centrifuged two more times. The plasma was then sterilized with a 0.2 μm Super Membrane Low Protein Binding filter (PALL Inc., Port Washington, NY, USA). Plasma was diluted (1:10) in culture medium and added into a 96-well plate seeded with 4T1 cells for MTT analysis.

**Western blot analysis.** 4T1 cells were incubated in GC solution at different concentrations (0, 10, and 100 μg/ml) for 24 and 48 h. Protein was then extracted from cells using protein lysis buffer (50 mM Tris-HCl, 120 mM NaCl, 0.5% NP-40) with 2% PMSF and quantified using the Bio-Rad Protein Assay (Bio-Rad Laboratories Inc., Hercules, CA, USA). Protein was mixed with sampling buffer (250 mM Tris-HCl (pH 6.8), 10% sodium dodecyl sulfate (SDS), 30% glycerol, 5% β-mercaptoethanol, 0.02% bromophenol blue), denatured with heating, and subjected to SDS-polyacrylamide gel electrophoresis. Gel was electrotransferred to nitrocellulose membrane (BioTraceTM NT, Pall, Port Washington, NY, USA) after electrophoresis, and the membrane was blocked with 4% milk in Tris-buffered saline with Tween-20 buffer (150 mM NaCl, 10 mM Tris-HCl (pH 8.0), and 0.1% Tween-20) for 2 h. The membrane was incubated with primary antibody overnight, and followed by HRP-conjugated secondary antibody. The membrane was rinsed with Western lightning plus-ECL (Perkin-Elmer Inc., Waltham, MA, USA) and the chemiluminescent signals were detected using the LAS-4000 gel imaging system (GE Healthcare Inc., Wauwatosa, WI, USA). The band densities were quantified using ImageJ software (version 1.46). The primary antibodies used in this study included anti-Twist-1, anti-Slug, anti-Snail and anti-E-cadherin (kindly provided by Dr. Muh-Hwa Yang at National Yang-Ming University, Taipei, Taiwan). Anti-glyceraldehyde 3-phosphate dehydrogenase antibodies were used as a control and were purchased from GeneTex Inc. (Irvine, CA, USA).

**Statistical analysis.** Experimental data were represented as the mean of three independent experiments ± S.D. Data were analyzed with t-test or Mann–Whitney test (for animal experiments), with three random regions were selected and photographed using a digital camera. We thank Dr. Yu Kang and Dr. Congjian Xu (Fudan University, Shanghai, China) for providing Act-βPase and PB-βk-MRFP plasmids for this work. We also thank Dr. Muh-Hwa Yang for providing antibodies for the EMT study. This research was supported in part by grants from the US National Institutes of Health (R21 EB015509-01), the US Fulbright Scholar Program, and Immunophotonics Inc. This research was also supported by the united grant of Hyperthermia for the treatment of metastatic tumors in rats. This research was supported in part by grants from the US National Institutes of Health (R21 EB015509-01), the US Fulbright Scholar Program, and Immunophotonics Inc. This research was also supported by the united grant of Hyperthermia for the treatment of metastatic tumors in rats. This research was supported in part by grants from the US National Institutes of Health (R21 EB015509-01), the US Fulbright Scholar Program, and Immunophotonics Inc.
35. Tran DD, Corsa CA, Biswas H, At R, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial–mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 2011; 9: 1644–1657.
36. Iacobelli S, Ranelletti FO, Longo P, Riccardi R, Mastrangelo R. Discrepancies between in vivo and in vitro effects of glucorticoids in myelomonocytic leukemic cells with steroid receptors. Cancer Res 1978; 38: 4257–4262.
37. Schug M, Stober R, Heise T, Mielke H, Gundert-Remy U, Godoy P et al. Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. Arch Toxicol 2013; 87: 337–345.
38. Schwengers E, Kelchtermans H, Mitters T, Gebies L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010; 12: R31.
39. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 291: 1001–1005.
40. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 2010; 32: 35–48.
41. Chen YL, Wang SY, Liu RS, Wang HE, Chen JC, Chiou SH et al. Remnant living cells that escape cell loss in late-stage tumors exhibit cancer stem cell-like characteristics. Cell Death Dis 2012; 3: e399.

42. Yang FY, Wang HE, Lin GL, Teng MC, Lin HH, Wong TT et al. Micro-SPECT/CT-based pharmacokinetic analysis of 99mTc-diethylenetriaminepentaacetic acid in rats with blood–brain barrier disruption induced by focused ultrasound. J Nucl Med 2011; 52: 478–484.
43. Yang FY, Wang HE, Liu RS, Teng MC, Li JJ, Lu M et al. Pharmacokinetic analysis of 111in-labeled liposomal Doxorubicin in murine glioblastoma after blood–brain barrier disruption by focused ultrasound. PLoS One 2012; 7: e45468.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/